Early Phase 1 Autoimmune Disease Clinical Trials
16 recruitingEarly Phase 1
What is a Early Phase 1 trial?
Early Phase 1 trials are the earliest stage of testing in humans. These small studies focus on how a drug is processed in the body and how it affects the body, often enrolling just a handful of participants to establish initial safety data.
Showing 1–16 of 16 trials
Recruiting
Early Phase 1
Allogeneic CD19/BCMA CAR-T for B Cell-Related Autoimmune Disease
IgA Nephropathy (IgAN)Autoimmune DiseasesSystemic Sclerosis (SSc)+3 more
The Children's Hospital of Zhejiang University School of Medicine15 enrolled1 locationNCT07507201
Recruiting
Early Phase 1
A Study of mRNA Encoding CD19/CD3 T Cell Engager (ABO2203) in Patients With Refractory Autoimmune Diseases
Autoimmune Diseases
Ruijin Hospital66 enrolled3 locationsNCT06747156
Recruiting
Early Phase 1
A Clinical Study of AFN50 in the Treatment of Autoimmune Diseases
Relapsed/Refractory Autoimmune Diseases
Beijing Boren Hospital18 enrolled1 locationNCT07448298
Recruiting
Early Phase 1
Clinical Study of AFN50 Injection in the Autoimmune Diseases
Autoimmune Diseases
AlphaNa Bioscience Company Limited18 enrolled1 locationNCT07408336
Recruiting
Early Phase 1
A Study of CNCT19 in the Treatment of Relapsed or Refractory Neurological Autoimmune Diseases
Neurological Autoimmune Diseases
Juventas Cell Therapy Ltd.18 enrolled1 locationNCT07275736
Recruiting
Early Phase 1
Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA U CAR-T Cell Injection for the Treatment of Relapsed/Refractory Autoimmune Diseases
Rheumatoid ArthritisSystemic Lupus ErythematosusAnti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis+3 more
Changhai Hospital60 enrolled1 locationNCT07246096
Recruiting
Early Phase 1
Exploratory Clinical Study of Second-generation CD19/BCMA Chimeric Antigen Receptor NK Cell Injection in Treating Paediatric B Cell-related Autoimmune Diseases
CARAutoimmune DiseasesPaediatric B Cell-related Autoimmune Diseases
The Children's Hospital of Zhejiang University School of Medicine12 enrolled1 locationNCT07283315
Recruiting
Early Phase 1
Safety and Efficacy Study of RXIM002 in Severe, Relapsed or Refractory Autoimmune Diseases
Relapsed/Refractory B Cell-Mediated Autoimmune Diseases
Ruijin Hospital27 enrolled1 locationNCT07322718
Recruiting
Early Phase 1
A Clinical Study to Evaluate the Safety and Efficacy of GT801 Injection in the Treatment of Moderate-to-Severe Refractory Autoimmune Diseases
Moderate to Severe Refractory Autoimmune Disease
Grit Biotechnology22 enrolled1 locationNCT07333118
Recruiting
Early Phase 1
CD19 CAR-T in the Treatment of Relapsed/Refractory Autoimmune Diseases
Autoimmune Diseases
Institute of Hematology & Blood Diseases Hospital, China15 enrolled1 locationNCT06680388
Recruiting
Early Phase 1
A Study of LUCAR-DKS1 in Subjects With Relapsed/Refractory Autoimmune Diseases
Relapsed/Refractory Autoimmune Diseases
Nanjing Legend Biotech Co.36 enrolled5 locationsNCT07095075
Recruiting
Early Phase 1
Anti-CD19/BCMA CAR-NK Cells in Patients With B Cell Mediated Autoimmune Disease
Autoimmune DiseasesSystemic Lupus ErthematosusMulti-Drug Resistant Nephrotic Syndrome+1 more
The Children's Hospital of Zhejiang University School of Medicine36 enrolled1 locationNCT06792799
Recruiting
Early Phase 1
GT719 Injection for Moderate to Severe Refractory Autoimmune Diseases
Autoimmune Diseases
Grit Biotechnology10 enrolled1 locationNCT07122076
Recruiting
Early Phase 1
A Clinical Study of CD19 CAR NK Cells for the Treatment of Relapsed/Refractory B-cell Related Autoimmune Diseases
Autoimmune Diseases
YANRU WANG15 enrolled2 locationsNCT06318533
Recruiting
Early Phase 1
Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System
Myasthenia GravisAutoimmune EncephalitisMultiple Sclerosis+7 more
Tongji Hospital36 enrolled1 locationNCT04561557
Recruiting
Early Phase 1
CD19-BAFF CAR-T Cells Therapy for Patients With Autoimmune Diseases
Autoimmune Diseases
Zhejiang University45 enrolled1 locationNCT06279923